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SUMMARY
Over 4 million patients suffer nosocomial infections annually in the European Union. This
study aimed to estimate the healthcare burden associated with healthcare-associated infections
(HAIs) following surgery in France, and explore the potential impact of infection control
strategies and interventions on the clinical and economic burden of disease. Data on the
frequency of HAIs were gathered from the 2010 Programme de Médicalisation des Systèmes
d’Information (PMSI), and cost data were taken from the 2009 Echelle Nationale de Coûts à
Méthodologie Commune (ENCC). It was estimated that 3% of surgical procedures performed
in 2010 in France resulted in infection, resulting in an annual cost of €57892715. Patients
experiencing a HAI had a signiﬁcantly increased mortality risk (4·15-fold) and an increased
length of hospital stay (threefold). Scenario analysis in which HAI incidence following surgery
was reduced by 8% (based on a study of the effectiveness of triclosan-coated sutures), suggested
that, annually, 20205 hospital days and €4588519 could be saved. Analyses of 20% and 30%
reductions in incidence (based on an estimate of the number of preventable nosocomial
infections) suggested that annual savings of €11548057 and €17334696, respectively, could be
made. New infection control interventions which reduce HAI incidence during hospitalization
for surgery have the potential to provide valuable cost savings to healthcare providers.
Key words: Cost, France, healthcare-associated infections, nosocomial infections, surgical site
infections.
INTRODUCTION
Annually, over 4 million patients within the 27
European Union member states acquire a nosocomial
infection, of whom approximately 37000 will die as a
result [1]. Surgical site infections (SSIs) are the third
most common form of healthcare-associated infection
(HAI), behind urinary tract (27%) and lower respirat-
ory tract (24%) infections, comprising 17% of cases
[1]. The economic impact of SSIs is considerable,
with an estimated burden on European healthcare
providers of €7 billion in 2008 [2]. Costs are driven
predominantly by increased length of hospital stay,
estimated to be an average 9·8-day increase compared
to patients not experiencing a SSI [3].
In France, surveillance of HAIs has been in place
since the early 1990s. It has been estimated that the
crude incidence of SSIs in France, between 1996 and
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2006, was 1·54% in patients undergoing either elective
or emergency surgery [4]. The incidence varied
depending on the surgical intervention, from 0·49%
for knee prosthesis to 9·24% for colon surgery [5].
Despite an increase in the number of patients under-
going surgical procedures, in particular patients
deemed to be at high risk of SSI, such as elderly
patients, analysis of temporal trends has shown that
the incidence of nosocomial infections in France has
decreased in recent years [5–7]. The reduction in
SSI incidence has been attributed, in part, to the suc-
cessful introduction of active surveillance programmes
such as the Infection du site Opératoire –Réseau
Alerte Investigation Surveillance des Infections
(ISO-RAISIN) and Incidence des Infections du Site
Opératoire (INCISO), and the utilization of infection
control strategies that have accompanied surveillance
[4, 8]. The majority of SSIs are preventable; with a
recent USA-based study ﬁnding that up to 55% of
cases could be avoided [9].
ISO-RAISIN data from 2007 showed that the most
common infectious causative agents of SSIs were
Escherichia coli (25%), Staphylococcus aureus (19%)
and Pseudomonas aeruginosa (10%) [10]. Of the ident-
iﬁed strains, 10% of E. coli isolates were cefotaxime-
or ceftriaxone-resistant, 19% of S. aureus were
methicillin-resistant and 25% of P. aeruginosa were
ceftazidime-resistant. The frequency of infection by
resistant strains of bacteria signiﬁcantly adds to the
burden of SSIs as more expensive second-line treat-
ments become necessary.
Published data describing the total economic bur-
den of nosocomial infections and SSIs in France are
currently lacking. A recent single-centre study found
that the mean additional cost per patient experiencing
a SSI, taking into account laboratory tests, radiology,
surgery, exploratory examinations and antimicrobial
agents, was €1814 [11]. The aim of the present study
was to estimate the healthcare burden associated
with SSIs, both nationally and by region, in France
and to explore the potential impact of infection con-
trol strategies on the overall clinical and economic
burden.
METHODS
Identiﬁcation of surgical procedures and incidence
of HAI
The frequency of 12 preselected surgical procedure
categories (Table 1) performed in France between
1 January 2010 and 31 December 2010 was quantiﬁed
through searching of the Programme de Médicalisa-
tion des Systèmes d’Information (PMSI) using 507
appropriate Classiﬁcation Commune des Actes Medi-
caux (CCAM) procedure codes, selected from about
8000 codes used to index hospital procedures in
France. The 12 procedure categories were chosen to
provide an overview of SSIs in France, but do not
encompass all surgical procedures performed in
2010, and therefore the total incidence is underesti-
mated. PMSI is a comprehensive database of hospital
visits in France since all hospitals, both public and pri-
vate, are legally obliged to report activity for col-
lation, otherwise remuneration for the procedure
performed is withheld by the local health authority
[12, 13]. It is recommended as an epidemiological
tool by the French guidelines for health economic
evaluation [14]. As well as detailing the procedure per-
formed using CCAM codes, the database contains
details of length of hospital stay, patients’ details
(such as age) and an anonymous patient identiﬁer to
allow future hospitalizations to be followed.
Table 1. Daily cost of hospital care following
healthcare-associated infection by surgical procedure,
in public and private hospitals
Surgical procedure
Daily cost of
care in public
hospitals (€)
Daily cost of
care in private
hospitals (€)
Amputation 276 171
Coronary artery
bypass
268 163
Thoracic or
abdominal artery
surgery
219 131
Thoracic or
abdominal vein
surgery
261 —
Kidney or pelvic
surgery
259 162
Caesarean 281 160
Colon and rectal
surgery
240 162
Bowel surgery 304 177
Laparoscopic
hysterectomy
293 189
Intracranial or
cerebrospinal ﬂuid
surgery
263 171
Prostate surgery 166 150
Organ transplant 290 172
€=2009 euros.
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Having identiﬁed patients undergoing surgical pro-
cedures in France, the incidence of SSIs was examined
by inspection of patients’ history subsequent to sur-
gery for the Classiﬁcation Statistique Internationale
des Maladies et des Problèmes de Santé Connexes
(ICD-10) codes relating to infection, namely T814
(Infection following a therapeutic or diagnostic pro-
cedure, not classiﬁed elsewhere), L02 (Cutaneous
abscess, furuncle, carbuncle), and Y95 (Nosocomial
infection). Since these codes are not speciﬁc to infec-
tion of the surgical site, data shown is for HAI inci-
dence following surgery.
Estimation of daily cost of care
Daily costs of care were calculated for both public and
private hospitals based on resource use and cost data
from the 2009 Echelle Nationale de Coûts à
Méthodologie Commune (ENCC). The ENCC pro-
vides costs of care, taking into account costs of a
range of factors, including medical professionals, drug
costs, and running costs of the medical unit (e.g. clean-
ing and laundry). It is possible to evaluate daily phys-
ician costs for public hospitals, but this is not the case
for private hospitals since physicians are reimbursed
per CCAM procedure performed rather than per day
of care administered, and therefore physician costs are
captured in public, but not private, hospitals. In this
analysis only costs allocated to the days of stay follow-
ing surgical procedures were included. The mean daily
cost of care, in 2009 euros (€), following each category
of surgical procedure is summarized in Table 1.
Health economic model
Having collected data on the length of stay in patients
with and without HAI, a health economic model was
constructed to evaluate cost differences between the
infection control scenarios. A bespoke model was
coded, with SQLite and Adobe Air used to manage
the database and present the results. A 1-year time
horizon was used with outcomes evaluated from a
hospital perspective. In this model HAI incidence
could be varied to examine the clinical and economic
impact of infection control interventions used. Model
inputs were length of stay associated with each pro-
cedure with and without HAI, daily cost of hospital
care following each procedure, and HAI incidence fol-
lowing each procedure. The model reported outputs of
number of hospital stays, number of hospital days of
care, and cost of care.
As well as examining the burden at current rates of
infection, three scenario analyses were performed in
which HAI incidence was varied. In the ﬁrst scenario
HAI incidence was reduced by 8%. This was based on
a recent study of the use of triclosan antibacterial
sutures, which found that SSI incidence was reduced
by 8% (7% vs. 15%) compared to the control arm in
which conventional sutures were used [15]. To exam-
ine the impact of less focused approaches that could
be used to reduce SSIs, scenarios with 20% and 30%
reduction in incidence were also analysed. These
were based on the upper and lower limits of an esti-
mate of the number of preventable nosocomial infec-
tions, made by the European Centre for Disease
Prevention and Control [1].
Statistical analysis
Descriptive statistics were used to summarize the clini-
cal and economic data from the analysis. Statistical
analysis was conducted to examine differences
between clinical outcomes in patients experiencing
HAI and those not experiencing HAI, based on the
data collected from PMSI. Hypothesis testing of the
difference between normally distributed variables
was performed using χ2 tests, while Mann–Whitney
U tests were used for non-normally distributed vari-
ables. Normality tests, to determine whether the
data were well modelled by a normal distribution,
were performed using Kolmogorov–Smirnov non-
parametric tests.
RESULTS
Incidence of SSI
The PMSI data showed that of 520715 selected surgi-
cal procedures performed between 1 January 2010
and 31 December 2010, 3·0% resulted in infection
(Table 2). Frequency of HAI was correlated with
Table 2. Summary of episodes of hospital care included
in the analysis (with and without HAI)
Without
HAI
With
HAI Total
Number of procedures 505195 15520 520715
Median length of stay
(days)
7 22 7
Number of deaths 10326 1293 11619
HAI, healthcare-associated infection.
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age, with 43·9% of cases occurring in patients aged
570 years, while only 15·1% of cases involved
patients aged <50 years (Fig. 1). The frequency of
HAI also varied with the type of surgery performed
(Table 3). Of the selected surgical procedures, the
group with the highest incidence of HAI was organ
transplant, with 13·1% of surgeries resulting in HAI.
Caesarean section had the lowest incidence of HAI,
with only 0·1% of procedures being followed by in-
fection. The clinical burden of HAI was greatest fol-
lowing colon and bowel surgery, comprising 49·1%
and 22·0%, respectively, of the total HAI cases.
Incidence also varied by region (Fig. 2). It was
found that the highest incidence of infection was in
Martinique (5·1%) and the lowest in French Guiana
(0·7%). Of the mainland French regions, the highest
incidence was found in Languedoc-Roussillon (4·2%)
and the lowest incidence in Alsace (2·2%). However,
when corrected for case mix it was found that inci-
dence rates were similar across regions. This suggests
that differences found between regions were due to
the number of high-risk procedures performed, rather
than other factors inﬂuencing HAI incidence. The
incidence rates in public and private hospitals showed
minimal variation, with 2·9% and 3·1% of procedures
resulting in HAI, respectively. Incidence rates by pro-
cedure were also found to be comparable for public
and private hospitals.
Clinical burden of SSI
HAI was associated with a statistically signiﬁcant
increase in mortality. The mortality rate in patients
experiencing a HAI was 8·3%, compared to 2·0% in
patients who did not (P<0·001), corresponding to a
4·15-fold relative increase (Table 3). The largest
increase in mortality rate was seen in the thoracic or
abdominal vein and thoracic or abdominal artery sur-
gery groups, where mortality rates increased over
50-fold, from 0·2% to 10·4%, and 2·3-fold, from
6·3% to 14·3%, respectively. Mortality rates did not
vary in public and private hospitals. Length of hospi-
tal stay was found to be non-normally distributed
(Kolmogorov–Smirnov D=0·253, P<0·01). Patients
experiencing HAI had a threefold longer hospital
stay than those who did not, with median length of
stay increasing from 7 days to 22 days (P<0·001).
When mean length of hospital stay following each
procedure was evaluated, it was found that HAI was
associated with at least a twofold longer stay follow-
ing all procedures (Table 3). Of particular note was
the almost tenfold increase following thoracic or
abdominal vein surgery, with mean length of stay
increasing from 3 days to 29 days following the pro-
cedure if HAI occurred.
Cost of SSI
The health economic modelling analysis suggested
that in 2010, HAIs led to an additional cost to public
and private hospitals of €43019936 and €14872779,
respectively (Table 4). This difference was driven not
by the rate of infection, since incidence rates were
found to be comparable, but by the increased number
of procedures performed in public hospitals and the
increased daily cost of care. A total of 86861 more
procedures were performed in public hospitals, result-
ing in 1856 further HAIs. The daily cost of care was
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Fig. 1. Distribution of hospital stays by age. HAI, Healthcare-associated infection.
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found to be signiﬁcantly higher in public hospitals for
all procedures, ranging from €122 per day increase for
care following intracranial surgery (€293 vs. €171) to
€88 per day increase following thoracic and abdomi-
nal artery surgery (€219 vs. €131). This was, at least
in part, driven by the exclusion of physicians’ costs
in the private sector.
The largest cost burden was that of HAI following
kidney or pelvic surgery, costing public hospitals
€16195572 per year and private hospitals €6735474
per year. An increased number of patients experienced
HAI in public hospitals, despite similar rates of infec-
tion (∼3% in both), due to the increased number
of procedures performed in public hospitals (12365
in public hospitals vs. 8283 in private hospitals).
Furthermore, daily costs of care following kidney or
pelvic surgery were €99 higher in public hospitals
than in private hospitals. Expenditure following kid-
ney or pelvic surgery equated to 38% and 45%, in pub-
lic and private hospitals, respectively, of additional
expenditure as a result of HAI. HAIs had a
particularly large cost burden following caesarean
(€13134821), amputation (€5055414) and coronary
artery surgery (€4910239), comprising 40% of addi-
tional expenditure, across public and private hospitals,
between these three procedures.
Exploratory infection control scenarios
An 8% reduction in HAI incidence, based on a recent
study into the reduction in SSIs associated with the
use of triclosan antibacterial sutures [15] was predicted
to result in a saving of 20205 hospital days per year,
across both public and private hospitals, resulting in
annual cost savings of €3406520 in public hospitals
and €1178999 in private hospitals. The bulk of the
cost savings came from reduced cost of HAI following
kidney or pelvic surgery, with public hospitals saving
€1294299 per year and private hospitals saving
€537516 per year, 40% of total savings (Figs 3, 4).
The analysis in which a 20% reduction in HAI
incidence was applied, based on the lower limit of
an estimate of the number of preventable nosocomial
infections by the European Centre for Disease
Table 3. Burden of HAI by procedure
Surgical procedure
Number of
procedures
performed
Procedures
resulting in
HAI (%)
Contribution
to the total
burden of
HAI following
surgery (%)
Mean length
of stay
without
HAI
(days)
Mean
length of
stay with
HAI
(days)
Mortality
rate without
HAI (%)
Mortality
rate with
HAI (%)
Amputation 24759 5·4 8·6 17 35 5·7 9·8
Coronary artery
bypass
18541 3·5 4·1 14 31 3·6 9·5
Thoracic or
abdominal
artery surgery
30145 4·1 7·9 13 35 6·3 14·3
Thoracic or
abdominal
vein surgery
35978 0·3 0·7 3 29 0·2 10·4
Kidney or pelvic
surgery
20619 3·0 4·0 11 24 1·3 6·9
Caesarean 170349 0·1 1·5 7 13 0·0 0·4
Colon and rectal
surgery
93430 8·2 49·1 14 29 4·5 8·1
Bowel surgery 31533 10·8 22·0 17 37 8·5 12·4
Laparoscopic
hysterectomy
69271 1·0 4·3 6 19 0·2 3·0
Intracranial or
cerebrospinal
ﬂuid surgery
6465 6·5 2·7 22 50 13·1 16·0
Prostate surgery 32865 3·3 6·9 9 20 0·3 2·3
Organ transplant 1742 13·1 1·5 42 62 12·0 12·7
Total 520715 3·0 100 14 32 2·0 8·3
HAI, Healthcare-associated infection.
Some procedures were classiﬁed as more than one type of surgery. Therefore the total number of procedures is not the sum of
the individual procedures.
Burden of healthcare-associated infections in France 2477
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268813000253
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 14:46:17, subject to the Cambridge Core terms of use, available at
Prevention and Control [1] suggested that 3185 HAI
cases could be avoided annually, resulting in 50871
hospital days saved. This was made up of 32758
days in public hospitals and 18113 days in private
hospitals. Cost savings of €8583202 per year and
€2964855 per year could be made in public and pri-
vate hospitals, respectively (Figs 3, 4). Healthcare
spending as a result of HAIs was reduced from
€57892715 to €46344658.
When a 30% reduction in HAI incidence was
applied, based on the upper limit of a European
Centre for Disease Prevention and Control estimate
of the proportion of nosocomial infections that
could be prevented [1], analysis suggested that 76373
hospital days per year could be saved as a result of
4781 HAI cases being avoided. Cost savings of
€12880036 per year could be made in public hospitals,
and €4454660 per year in private hospitals (Figs 3, 4).
This saving of €17334696 represents a 30% reduction
in healthcare spending as a result of HAIs.
DISCUSSION
The present study has quantiﬁed part of the consider-
able clinical and economic burden of SSIs on the
French healthcare system, where about 3% of the
included surgical procedures resulted in infection.
The incidence of HAI following surgery increased
with patients’ age and varied depending on the surgi-
cal procedure performed. Included HAIs led to a
4·15-fold increase in post-surgery mortality, a three-
fold increase in length of hospital stay and an annual
cost burden of €57892715. The largest costs were seen
in patients experiencing HAI after kidney or pelvic
surgery. The current analysis underestimates the
total burden of SSIs on the French health economy
for two reasons. First, only a predeﬁned set of surgical
procedures were included in the analysis, not all the
surgical procedures performed in France in 2010.
Furthermore, the ICD-10 codes used captured only
infections reported during the initial hospital stay.
Since not all SSI cases were identiﬁed in this analysis,
the clinical and economic estimates are conservative
and the burden to the French health economy is
expected to be greater. Scenario analysis suggests
that reduction in HAI incidence by 8%, 20% and
30% will result in savings of €4588519, €11548057
and €17334696, respectively. These are substantial
cost savings, made predominantly in public hospitals
due to the increased number of surgical procedures
performed and the increased daily cost of care. The
frequency of surgical procedures involving patients
 1% incidence of HAI
1–2% incidence of HAI
2–3% incidence of HAI
3–4% incidence of HAI
5% incidence of HAI
Guadeloupe
Martinique
French Guiana
Réunion
Fig. 2. Incidence of healthcare-associated infection (HAI) following surgery in the 27 regions of France.
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at high risk of SSI is increasing, and therefore the use
of infection control strategies is likely to become
increasingly important in the future.
One of the major strengths of the present study is
the robust epidemiological data on which the health
economic model is based. PMSI provides a detailed
account of hospital stays and allows the number of
procedures and treatments performed in a given time-
frame to be accurately determined. Furthermore, the
age of the patient and the post-operative clinical con-
sequences can be accurately assessed using the anon-
ymous patient identiﬁer. In this analysis, 507 CCAM
codes relating to preselected surgical procedures
were used to identify treatments of interest, giving a
comprehensive list of procedures performed, while
the use of ICD-10 codes relating to HAI allows accu-
rate quantiﬁcation of HAI incidence following surgery
during the initial hospital stay. The bespoke health
economic model developed for this analysis, based
on these data, may be a valuable tool for future econ-
omic evaluations of infection control strategies and
interventions in the French setting.
An assumption of this analysis is that the daily cost
of care following surgical procedures is the same in
patients experiencing HAI and those not experiencing
HAI. It may be the case that patients with HAI would
require not only a longer period of care, taken into
account through the increased length of hospital
stay, but also require more intense and expensive
care during hospitalization. This may be through
increased volume of diagnostic tests to identify the
causative pathogen, intensiﬁed antimicrobial treat-
ments (including more expensive second-line therapy
if the causative agent is resistant to ﬁrst-line treat-
ments), and increased nursing staff time. Given this
conservative assumption, cost savings reducing SSI
incidence may be greater than those suggested in this
analysis.
Table 4. Additional length of hospital stay and additional costs associated with healthcare-associated infection
following surgery for public and private hospitals in France
Surgical
procedure
Public hospitals Private hospitals
Additional
length of
hospital stay
(days)
Additional
cost (€)
Additional cost
per procedure
resulting in HAI
(€)
Additional
length of
hospital stay
(days)
Additional
cost (€)
Additional cost
per procedure
resulting in HAI
(€)
Amputation 14095 3890220 4968 6814 1165194 3078
Coronary artery
bypass
13166 3528488 4556 8477 1381751 2771
Thoracic or
abdominal artery
surgery
905 198195 4818 292 38252 2882
Thoracic or
abdominal vein
surgery
3297 547302 4316 — — —
Kidney or pelvic
surgery
62052 16195572 3654 41577 6735474 2268
Caesarean 40439 10473701 1554 16632 2661120 960
Colon and rectal
surgery
4851 1363131 4215 2319 375678 2430
Bowel surgery 9010 2162400 4800 594 105138 3540
Laparoscopic
hysterectomy
4808 1461632 3952 3096 585144 2457
Intracranial or
cerebrospinal
ﬂuid surgery
3478 1019054 8497 7334 1254114 4959
Prostate surgery 6347 1669261 2893 3133 469950 1650
Organ transplant 1762 510980 5800 587 100964 3440
Total 164210 43019936 — 90855 14872779 —
HAI, Healthcare-associated infection.
€=2009 euros.
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An important limitation of the present analysis is
that it does not capture the costs of achieving 8%,
20% and 30% reductions in HAI incidence following
surgery. However, the analysis does show the
threshold at which an intervention to achieve this
reduction will be cost saving. For example, if an infec-
tion control strategy resulting in an 8% reduction in
HAI could be introduced in public hospitals at
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Fig. 3. Cost saving by reducing the incidence of healthcare-associated infections (HAIs) following surgery by 8%, 20%
and 30% in public hospitals. € = 2009 euros.
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Fig. 4. Cost saving by reducing the incidence of healthcare-associated infections (HAIs) following surgery by 8%, 20%
and 30% in private hospitals. € = 2009 euros.
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an annual cost of less than €3400000, healthcare pro-
viders would have reduced expenditure. While includ-
ing the costs of interventions to achieve reductions in
HAI following surgery was beyond the scope of the
present analysis, the potential for signiﬁcant cost sav-
ings as a result of interventions that reduce HAI inci-
dence following surgery is worthy of further
investigation.
The risk of SSI is dependent on the type and viru-
lence of the infecting bacteria, and the immunological
status of the host. Patients’ characteristics and comor-
bidities play a key role in determining the likelihood of
SSI. Factors increasing the susceptibility of patients
to SSI include advanced age, poor nutritional status,
diabetes, smoking, obesity, infection remote to the
surgical site and lengthy preoperative hospitalization.
Due to the increased resource use and cost of hospital
care for patients experiencing a SSI, infection control
strategies to reduce the incidence are important, par-
ticularly in patients at the highest risk.
While it is acknowledged that not all SSIs can be
prevented, evidence suggests that the current level of
incidence can be reduced [1–3]. The majority of SSIs
occur at superﬁcial sites around foreign material left
in the wound [16]. One potential avenue for improving
infection control is in the choice of sutures, which are
known to provide a focal point for bacterial coloniza-
tion, act as a vehicle to transport bacteria into the
wound and afford a repository for bacteria in the
suture knot. Use of triclosan-coated sutures reduces
SSIs by preventing bacterial colonization of the
wound around the suture, due to the presence of an
antimicrobial. Triclosan is a broad-spectrum antimi-
crobial agent, possessing mostly antibacterial, but
also some antifungal and antiviral properties. Use
of triclosan-coated sutures has been shown to reduce
SSI incidence by 8% (7% vs. 15%) in a comparison
with conventional sutures [15]. Examination of this
beneﬁt in the present scenario analysis suggests
that this reduction in SSI incidence may have a
substantial impact on both the clinical and econ-
omic burden, reducing the number of hospital
stays, length of stay and cost of care by as much as
€4588519 per year. Further economic evaluation of
the beneﬁt of introduction of infection control inter-
ventions such as triclosan antibacterial sutures in the
French setting may be warranted based on these
observations.
The World Health Organization and the Centre for
Disease Control and Prevention have issued guidelines
detailing pre-, peri- and post-operative infection
control actions that can be used to reduce the inci-
dence of SSIs [17, 18]. Preoperatively patients should
be treated to resolve infections remote from the surgi-
cal site and appropriate disinfection of the skin at the
surgical site should take place, with shaving only per-
formed if absolutely necessary [17, 18]. If the patient is
considered at high risk of SSI, a prophylactic dose of
an appropriate antimicrobial should be administered,
ideally intravenously, at a time to establish a bacteri-
cidal concentration at the operational site [17, 18].
Surgical team members should follow good practice
guidelines for hand washing and preoperative aseptic
procedures [17, 18]. During the surgical procedure,
surgical team members should use surgical masks,
caps, gowns, gloves and drapes and replace these
items when they become soiled [17, 18]. The operating
theatre should be cleaned using a hospital-approved
disinfectant and good practice used to maintain ster-
ility of surgical instruments [17, 18]. Air within the
operating theatre should be changed at least 15
times per hour, with three of these being with fresh
air, and ﬁltering should take place using an appropri-
ate ﬁlter [17, 18]. In the post-operative period, sterile
dressing should be used and sterile techniques should
be adhered to during dressing changes [17, 18].
Patients should undergo post-operative surveillance,
including post-discharge if required, with any SSI
assessed and reported appropriately [17, 18]. SSI
rates should then be conveyed to surgical team mem-
bers [17, 18]. All of these steps offer opportunities to
reduce SSI incidence. Some estimates have suggested
that up to 55% of SSIs can be prevented [5]. The pre-
sent study used conservative estimates of an overall
reduction in incidence of 20–30% in SSIs. The ana-
lyses suggest that substantial reductions in healthcare
expenditure could occur if SSI incidence is reduced.
With greater decreases in SSI incidence larger cost
savings can be expected, as the required number of
hospital days of care will be reduced beyond the levels
estimated in this study.
The present study has quantiﬁed the substantial
economic burden that SSIs following a limited selec-
tion of procedures place on the healthcare system in
France to be €57892715 per year. However, our analy-
sis was conservative and the total burden is expected
to be greater, both clinically and economically. New
infection control interventions which reduce SSI inci-
dence have the potential to lessen the clinical and
economic burden, providing valuable cost savings to
healthcare providers and should be the subject of
future health economic evaluations.
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